ArticleBMC infectious diseases2026
Temporal trends and clinical outcomes of pediatric invasive fungal diseases: a ten-year retrospective study from a tertiary-care center in Thailand.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Persistent Non-Journal of fungi (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal diseases (IFDs) remain an important cause of morbidity and mortality among immunocompromised children. Changes in diagnostic criteria and increasing use of antifungal prophylaxis may influence the epidemiology and clinical presentation of pediatric IFDs. Longitudinal data from Southeast Asia remain limited. This study aimed to characterize temporal trends, clinical features, and outcomes of pediatric IFDs using the 2020 EORTC/MSGERC criteria.
methodsWe retrospectively reviewed children aged 0-15 years diagnosed with IFDs at a tertiary-care hospital in Bangkok, Thailand, from 2014 to 2023. IFD episodes were classified as proven, probable, or possible according to the 2020 EORTC/MSGERC criteria and categorized by causative organism. Temporal trends, clinical characteristics, antifungal prophylaxis exposure, and outcomes were analyzed.
resultsAmong 156 patients, 171 IFD episodes were identified: invasive aspergillosis (60 episodes), invasive candidiasis (61), Pneumocystis pneumonia (33), cryptococcosis (5), other invasive mold infections (8), and endemic mycoses (4). Invasive aspergillosis and Pneumocystis pneumonia demonstrated greater year-to-year variability with higher case numbers in later years, whereas invasive candidiasis occurred consistently throughout the study. A proportion of IFD episodes occurred despite antifungal prophylaxis, including 23.3% of invasive aspergillosis, 8.2% of invasive candidiasis, and 12.1% of Pneumocystis pneumonia. Hematologic malignancies were the most common underlying conditions among children with invasive aspergillosis (68.3%) and Pneumocystis pneumonia (27.3%). Invasive candidiasis primarily affected infants and young children with chronic conditions, including chronic liver or gastrointestinal disease (25.4%) and congenital heart disease (25.4%), and was strongly associated with central venous catheter use (88.9%). Candida albicans remained the most common pathogen, with overall low antifungal resistance. The clinical manifestations were non-specific and overlapped across pathogens, most commonly presenting with fever and organ-specific symptoms. Ninety-day all-cause mortality was 20.3% for aspergillosis, 24.8% for candidiasis, and 12.9% for Pneumocystis pneumonia.
conclusionsPediatric IFDs remained associated with substantial mortality despite evolving diagnostic criteria and increasing use of antifungal prophylaxis, underscoring the need for improved diagnostic and preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.